This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CKD-732, beloranib IV
BioMedTracker has separate profiles for the intravenous and subcutaneous forms of beloranib. Please also see ZGN-440 (beloranib).
ZGN-433 is a methionine aminopeptidase 2 (MetAP2) inhibitor. Zafgen believes that in obesity, activation of stress pathways, such as extracellular regulated kinase (ERK), leads to changes in fat and cholesterol metabolism, and to the stimulation of the body’s inflammation cascades, resulting in overproduction of fat by the liver and reduced availability of fat stored in adipose tissue. In essence, the body blocks away calories that otherwise could be used productively as an energy source. Zafgen believes that Beloranib reduces the activity of these stress mediators, restoring balance to fat metabolism and reducing inflammation.
Specifically, Zafgen believes that MetAP2 inhibition leads to attenuated ERK phosphorylation, attenuated cellular stress cascade, gene expression changes for SREBP and ROR pathways, and metabolite and hormonal changes. In turn, this is thought to cause reduced hunger and food intake, reduced fat synthesis, increased fat burning, reduced cholesterol synthesis, and reduced inflammation.
Deal Structure: ZGN-433 was initially developed by Chong Kun Dang (CKD) Pharmaceuticals. Zafgen holds exclusive worldwide rights (exclusive of Korea) for development and commercialization of ZGN-433.
Partners: Chong Kun Dang Pharmaceutical Corp.
Additional information available to subscribers only: